ICR to Use AB Sciex Mass Spec System in Cancer Metastasis Research
The aim of the agreement to use the TOF/TOF 5800 System is to standardize methods for tissue imaging.!--h2>
The Institute of Cancer Research (ICR) is working with AB Sciex to standardize advanced methods of mass spectrometry-based tissue imaging. ICR’s research into cancer metastasis focuses on communication between cells associated with the spread of the disease. The goal is to find molecules that can be targeted with new drugs.
ICR will use AB Sciex’ TOF/TOF 5800 System, a MALDI-TOF/TOF mass spectrometry system. AB Sciex—formerly a joint venture of Applied Biosystems and MDS Analytical Technologies—says the system enables scientists to achieve in less than a day what takes more than weeks on other MALDI-based products.
ICR and AB Sciex will conduct nontargeted discovery and will look for and investigate how proteins present in specific regions of the tumor enhance metastatic progression. “This collaboration with AB Sciex on mass spectrometry-based imaging will help us discover new molecules that are critical to cancer spread,” states Janine Erler, team leader with ICR.